Sanofi (SNY)
After hours:
| Previous Close | 45.93 |
| Open | 46.76 |
| Bid | 46.19 x 500 |
| Ask | 46.24 x 500 |
| Day's Range | 46.01 - 46.90 |
| 52 Week Range | 42.63 - 57.82 |
| Volume | |
| Avg. Volume | 1,876,456 |
| Market Cap | 115.774B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 20.19 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.04 (4.41%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | N/A |
- Insider Monkey
10 Best Weight Loss Drug Stocks to Buy Now
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]
- Reuters
UPDATE 2-Cyclicals drive modest gains across European stocks
The continent-wide STOXX 600 index closed up 0.2%, led by a 1.7% gain in the basic resources sector as copper prices hit their highest in more than 14 months. "Recent inflation trends in Europe stand in stark contrast to what is happening in the U.S.," as per strategists at BCA Research. "This divergence in inflationary dynamics will force the ECB to be more dovish than the Fed."
- Reuters
UPDATE 2-Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did not disclose the financial terms of the deal. The agreement, which still needs to be finalized, will resolve most of the lawsuits against the French pharmaceutical company in U.S. state courts, with the exception of Delaware where the majority of the cases are pending.
